Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and Leukemia, Plasma Cell

pyrazines has been researched along with Leukemia, Plasma Cell in 37 studies

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (37.84)29.6817
2010's23 (62.16)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A1
Inui, Y; Kanakura, Y; Kataoka, S; Kawata, S; Kubo, M; Maeda, T; Matsunaga, H; Matsuura, N; Ueda, S1
Chatziaggelidou, C; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kyrtsonis, MC; Spyridis, N; Stefanoudaki, A; Symeonidis, A; Terpos, E; Verrou, E; Zervas, K1
An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D1
Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH1
Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S1
Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S1
de Zoysa, JR; Hutchison, CA; Lam-Po-Tang, M; Tan, J1
Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Tomita, S; Wakabayashi, M1
Bay, JO; Ravinet, A; Tournilhac, O1
Al-Nawakil, C; Bardet, V; Bourry, E; Bouscary, D; Chapuis, N; Choquet, S; Dreyfus, F; Park, S; Roux, C; Tamburini, J1
Batár, P; Kiss, A; Méhes, L; Telek, B; Udvardy, M1
Billet, A; Chaby, G; Chatelain, D; Christophe, O; Dadban, A; Damaj, G; Lenglet, A; Lok, C; Marolleau, JP; Royer, R; Thuillier, D; Vaida, I; Viseux, V1
Bernardeschi, P; Ferreri, MI; Fiorentini, G; Giustarini, G; Montenora, I; Pirrotta, MT; Simi, P1
Abdul-Jaleel, M; Candelaria-Quintana, D; Libby, E; Moualla, H; Rabinowitz, I1
Mele, G; Melpignano, A; Pinna, S; Quarta, G1
Chanan-Khan, A; Deeb, G; Lee, K; Miller, KC; Sher, T1
Liedtke, M; Medeiros, BC1
Candoni, A; De Muro, M; De Stefano, V; Ferrara, F; Fianchi, L; Galieni, P; Gozzetti, A; Leone, G; Musto, P; Pagano, L; Petrucci, MT; Pogliani, EM; Pulsoni, A; Specchia, G; Valentini, CG; Venditti, A; Visani, G; Visco, C1
Brunson, CY; Costa, LJ; Milligan, L; Rivell, GL; Stuart, RK1
D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O1
Bocchia, M; D'Arena, G; D'Auria, F; Defina, M; Gozzetti, A; Musto, P; Papini, G; Statuto, T; Steduto, T1
Imagawa, J; Kimura, A; Kinoshita, M; Mihara, K; Mino, T; Sakai, A; Yoshida, T1
Chigira, N; Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shirane, S; Sugimoto, K; Wakabayashi, M1
Anderson, KC; Lokhorst, HM; Richardson, PG; van de Donk, NW1
Miwa, A1
Aguado, B; Alegre, A; Bladé, J; Esparís-Ogando, A; Gutiérrez, N; Mateo, G; Pandiella, A; San Miguel, JF; Schenkein, D1
Herrington, JD; Jaskiewicz, AD; Wong, L1
Andreesen, R; Grassinger, J; Hennemann, B; Südhoff, T1
Arpaci, F; Ataergin, S; Cetin, T; Gunhan, O; Kaya, A; Kaya, T1
Alexander, HD; Cavanagh, JD; Drake, M; Finnegan, DP; Kettle, P; Matthews, C; Morris, TC; Popat, R; Wachsman, W1
Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Lotze, C; Schüler, F1
Capalbo, S; Chiefa, A; Delia, M; Diomede, D; Liso, V1
D'Arena, G; Ferrara, F; Filardi, N; Gay, F; Guariglia, R; Guglielmelli, T; Musto, P; Palumbo, A; Pitini, V; Rossini, F1
Cho, Y; Kim, BS; Kim, J; Kim, SJ; Seo, BK1
Ali, R; Beksac, M; Ozcelik, T; Ozkalemkas, F; Ozkan, A; Ozkocaman, V; Tunali, A1
Gastari, V; Hadjiaggelidou, C; Katodritou, E; Terpos, E; Verrou, E; Zervas, K1

Reviews

6 review(s) available for pyrazines and Leukemia, Plasma Cell

ArticleYear
Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Thalidomide

2013
[Plasma cell leukemia].
    Bulletin du cancer, 2014, Volume: 101, Issue:11

    Topics: Aged; Antineoplastic Agents; Biomedical Research; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Prognosis; Pyrazines; Rare Diseases; Thalidomide

2014
Plasma cell leukaemia and other aggressive plasma cell malignancies.
    British journal of haematology, 2010, Volume: 150, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide

2010
Plasma cell leukemia: concepts and management.
    Expert review of hematology, 2010, Volume: 3, Issue:5

    Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasms, Second Primary; Palliative Care; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2010
Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:11

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Boronic Acids; Bortezomib; Fatal Outcome; Humans; Leukemia, Plasma Cell; Male; Melphalan; Pleural Effusion, Malignant; Prednisone; Pyrazines; Treatment Failure

2012
How I treat plasma cell leukemia.
    Blood, 2012, Sep-20, Volume: 120, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Middle Aged; Prognosis; Pyrazines; Transplantation, Autologous

2012

Other Studies

31 other study(ies) available for pyrazines and Leukemia, Plasma Cell

ArticleYear
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy

2013
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    American journal of hematology, 2014, Volume: 89, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Treatment Outcome

2014
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous

2014
Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Plasmacytoma; Prognosis; Proteasome Inhibitors; Pyrazines; Recurrence; Republic of Korea; Retrospective Studies; Salvage Therapy

2014
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Hypertension, Pulmonary; Induction Chemotherapy; Lenalidomide; Leukemia, Plasma Cell; Male; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide

2014
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Neoplasms, Second Primary; Pyrazines; Thalidomide; Treatment Outcome

2015
Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
    Nephrology (Carlton, Vic.), 2014, Volume: 19, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Remission Induction; Renal Dialysis; Thalidomide; Treatment Outcome

2014
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Female; Humans; Immunohistochemistry; Lenalidomide; Leukemia, Plasma Cell; Leukocyte Common Antigens; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Pyrazines; Remission Induction; Thalidomide; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine

2014
Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Treatment Outcome

2008
[Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
    Orvosi hetilap, 2008, Oct-12, Volume: 149, Issue:41

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Leukemia, Plasma Cell; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Transplantation, Autologous; Treatment Outcome

2008
[Bortezomib-induced eruption: Sweet syndrome? Two case reports].
    Annales de dermatologie et de venereologie, 2009, Volume: 136, Issue:5

    Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Colchicine; Dexamethasone; Female; Humans; Leukemia, Plasma Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Skin Ulcer; Sweet Syndrome; Treatment Outcome

2009
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Female; Humans; Leukemia, Plasma Cell; Multiple Myeloma; Pyrazines; Recurrence

2010
Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.
    American journal of hematology, 2010, Volume: 85, Issue:9

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Melphalan; Prednisolone; Pyrazines; Remission Induction

2010
Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
    Clinical therapeutics, 2010, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Retrospective Studies

2010
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Outcome; Young Adult

2011
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.
    American journal of hematology, 2011, Volume: 86, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Resistance, Neoplasm; Hospitals, University; Humans; Immunologic Factors; Leukemia, Plasma Cell; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis

2011
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine

2012
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
    British journal of haematology, 2012, Volume: 157, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasms, Second Primary; Pyrazines; Recurrence; Remission Induction; Thalidomide

2012
[Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Hyperbilirubinemia; Leukemia, Plasma Cell; Prednisolone; Pyrazines; Severity of Illness Index; Treatment Outcome

2012
[Diagnosis and treatment for plasma cell leukemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Plasma Cell; Melphalan; Pyrazines; Rituximab; Thalidomide

2012
Bortezomib is an efficient agent in plasma cell leukemias.
    International journal of cancer, 2005, Apr-20, Volume: 114, Issue:4

    Topics: Anemia; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Pyrazines; Thrombocytopenia; Time Factors

2005
Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
    Pharmacotherapy, 2005, Volume: 25, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Pyrazines; Tumor Lysis Syndrome

2005
Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.
    Annals of hematology, 2006, Volume: 85, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Mobilization; Humans; Immunophenotyping; Leukemia, Plasma Cell; Pyrazines; Remission Induction; Treatment Outcome

2006
VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
    American journal of hematology, 2006, Volume: 81, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Etoposide; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Protease Inhibitors; Pyrazines; Remission Induction

2006
Bortezomib is effective in primary plasma cell leukemia.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:8

    Topics: Bone Marrow Examination; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Treatment Outcome

2006
Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
    Onkologie, 2007, Volume: 30, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunoglobulin A; Immunoglobulin Light Chains; Leukemia, Plasma Cell; Male; Multiple Myeloma; Pyrazines; Retreatment; Transplantation Chimera; Transplantation, Homologous

2007
Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Pyrazines; Skull; Tomography, X-Ray Computed; Treatment Outcome

2007
Efficacy and safety of bortezomib in patients with plasma cell leukemia.
    Cancer, 2007, Jun-01, Volume: 109, Issue:11

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Survival Rate

2007
Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:5

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Plasma Cell; Male; Pyrazines

2007
Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Treatment Outcome

2007
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
    Leukemia research, 2008, Volume: 32, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Immunophenotyping; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Treatment Outcome

2008